Summary of TIP857: S&P Global, Novo, Deckers Brands w/ Stig Brodersen, Tobias Carlisle, & Hari Ramachandra

Overview of TIP857: S&P Global, Novo, Deckers Brands w/ Stig Brodersen, Tobias Carlisle, & Hari Ramachandra

This episode is a value-investing roundtable where Stig Brodersen, Tobias Carlisle, and Hari Ramachandra each pitch a stock that the market has cooled on: Novo Nordisk, S&P Global, and Deckers Brands. The discussion centers on why these businesses may be undervalued, what risks the market is pricing in, and which long-term catalysts could still surprise to the upside.

Key Takeaways

• The theme of the episode is “out-of-favor quality”: all three investors focus on strong businesses that have recently lost market enthusiasm.
• Each pitch balances valuation, durability, and downside protection rather than aggressive near-term upside.
• A major discussion thread throughout the episode is whether AI, regulation, and competitive disruption are genuinely threatening these businesses or merely creating short-term fear.
• The group repeatedly returns to the idea that market sentiment has likely overshot fundamentals, especially for companies with strong brands, recurring demand, and disciplined capital allocation.

Hari Ramachandra’s Pitch: Novo Nordisk (NVO)

Why it looks attractive

• Novo Nordisk was once the most valuable company in Europe and is now down sharply from its highs.
• It trades at around 12x forward earnings, which Hari argues already assumes a very pessimistic outcome.
• The company remains a 100+ year old pharmaceutical franchise with strong positioning in diabetes and obesity.

Why the market is pessimistic

Hari highlighted three main concerns:

• Eli Lilly has taken the lead in the GLP-1 / obesity drug race, especially with more effective treatments.
• Medicare price negotiations and patent expirations could pressure margins.
• The company has guided down expectations and is investing heavily in future pipeline development, creating uncertainty.

Bull case

• Novo still has a massive global market in obesity and diabetes.
• A new pill-based obesity drug could become a major growth driver.
• The company’s next-generation pipeline, especially amicretin, could materially change the narrative if successful.

Return expectations

• Base case: roughly 8%–10% annualized over five years, including dividends.
• Bull case: potentially 18%–22% annualized if new drugs succeed.
• Hari views it as a quality business at a discounted price, not a classic deep-value bargain.

Discussion points

• Tobias framed the obesity drug market as an arms race, not necessarily a winner-take-all market.
• Stig noted the cultural significance of Novo in Denmark and emphasized the importance of thinking about the system and innovation pipeline, not just patent cliffs.
• The group agreed that the key question is whether Novo can regain efficacy leadership or at least remain a strong number two.

Stig Brodersen’s Pitch: S&P Global (SPGI)

Why he bought it

• Stig said he initiated a new position just hours before recording, his first new position in over a year.
• He found the idea by screening 13F filings and noticing repeated buying from respected investors.
• He was attracted by the combination of:
  • a wide moat
  • strong recurring revenue
  • and a valuation that looked more reasonable than usual

Business quality

S&P Global was described as one of the world’s best businesses, with four main segments:

• Ratings: about half of operating income
• Indices: small share of revenue but very high margins
• Market intelligence: includes products like Capital IQ
• Energy: smaller segment

Why the market is concerned

• Some investors worry about private credit and structural changes in debt issuance.
• The market intelligence business may face pressure from AI tools and startup competitors.
• The stock had previously traded at much higher multiples, so some of the current price compression reflects multiple de-rating.

Stig’s view on AI risk

• He thinks AI risk is overstated for the core ratings and index businesses.
• The market intelligence unit may be more exposed, but it is not the main earnings engine.
• He sees the concern as real, but not enough to undermine the overall thesis.

Valuation and return profile

• Stig estimated intrinsic value around $450–$500 per share.
• At his purchase price near $399, he sees roughly 10%–15% annualized returns as plausible.
• His view: the business is cheap relative to its quality, not cheap in an absolute sense.

Management and capital allocation

• He liked management’s willingness to spin off non-core assets and possibly simplify the business.
• He also noted insider buying and a generally shareholder-friendly tone, though not overly aggressive buybacks.

Tobias Carlisle’s Pitch: Deckers Brands (DECK)

Why it stands out

• Deckers owns Hoka and Ugg, both strong consumer brands with loyal followings.
• It trades around 11x earnings and has $1.6 billion in net cash with no debt.
• Tobias sees it as a clean business with a very attractive balance sheet and disciplined capital allocation.

Brand and business mix

• Hoka: the growth engine, though growth has slowed recently
• Ugg: a more mature brand, but still profitable and durable
• The company is asset-light and relies heavily on outsourced manufacturing, which helps returns on capital.

Why the stock is cheap

• Growth has slowed, especially at Hoka.
• Consumer discretionary stocks are under pressure from:
  • tariffs
  • higher interest rates
  • consumer squeeze
  • weaker discretionary spending
• The market may also be discounting a more cautious outlook for fashion/brand cycles.

Capital allocation strengths

• Deckers is aggressively buying back stock.
• Buybacks have been substantial and management appears disciplined.
• Tobias emphasized that this kind of capital allocation can meaningfully support long-term returns.

Scenario analysis

• Bear case: low growth, multiple compression, fair value around $72
• Base case: modest growth and a steady multiple, fair value around $110–$115
• Bull case: renewed growth and a higher multiple, fair value around $160

Tobias’s conclusion

• Deckers is not as “moaty” as S&P Global or as institutionally entrenched as Novo Nordisk.
• But it offers a much deeper discount, which makes it attractive to him.
• He sees it as a clean, shareholder-friendly business with enough quality to justify the risk.

Main Themes Across the Episode

1. Quality businesses can be cheap when sentiment turns

All three ideas are strong franchises, but the market currently sees them as:

• slowing
• under threat
• or facing structural headwinds

2. Valuation matters more when growth normalizes

Each pitch depends on the idea that:

• the business is still healthy
• the market has overreacted
• and long-term returns can still be attractive even if growth is more modest than before

3. AI is a real question, but not always equally relevant

• For S&P Global, AI may affect market intelligence more than ratings.
• For pharma, the conversation turned to how AI companies may try to use regulation as a moat.
• The group broadly agreed that not all AI threats are equally meaningful.

4. Capital allocation is a major source of value

• S&P’s spinoff strategy
• Deckers’ buybacks
• Novo’s pipeline investment all show how management decisions can shape long-term returns as much as the underlying business.

Notable Insights

• Hari on Novo Nordisk: The market is pricing Novo as if it has gone from a great company to a mediocre one.
• Stig on S&P Global: AI concerns are real, but the market intelligence business is not the core thesis.
• Tobias on Deckers: If a company is cheap enough and has a strong buyback program, downside can be cushioned even if growth is merely decent.

Bottom Line

This episode is a classic value-investing debate about whether the market has become too pessimistic about three high-quality companies:

• Novo Nordisk: cheap, but facing real competitive and pipeline risks
• S&P Global: exceptional business, with AI and valuation concerns creating an opening
• Deckers: a clean, cash-rich consumer brand business trading at a low multiple

The overall message: when high-quality businesses fall out of favor, the best opportunities often come from separating temporary narrative fear from permanent fundamental damage.